{"url_path":"/sec/adgm/8-k/2026-05-21/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/2006986/0001104659-26-065180-index.html","accession_number":"0001104659-26-065180","cik":"0002006986","ticker":"ADGM","issuer_name":"Adagio Medical Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2006986/0001104659-26-065180-index.html","primary_entity_key":"0002006986","primary_entity_name":"Adagio Medical Holdings, Inc."},"word_count":61,"has_tables":true,"body_markdown":"**Item 8.01 Other Events**\n\n \n\nOn May 21, 2026, Adagio Medical Holdings, Inc.\nissued a press release entitled “Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation\nSystem for the Treatment of Ventricular Tachycardia.” The full text of the press release is attached hereto as Exhibit 99.1 to this\nCurrent Report on Form 8-K and incorporated herein by reference."}